Program

Check back for updates on the 2019 Genitourinary Cancers Symposium program.

The 2019 Genitourinary Cancers Symposium will feature an array of multidisciplinary sessions covering prostate, renal, urothelial, penile, testicular, and adrenal cancers. World-renowned faculty will present on the most clinically relevant topics across these disease sites with an emphasis on multimodality therapy and value in cancer care.

7:00 AM-7:45 AM Complimentary Continental Breakfast
7:00 AM-6:30 PM Exhibits Open
7:45 AM-9:30 AM Welcome and General Session 1: Optimizing Diagnosis and Treatment of Clinically Significant Nonmetastatic Prostate Cancer

Jason A. Efstathiou, MD, DPhil—Chair
Massachusetts General Hospital

Himisha Beltran, MD—Chair
Dana Farber Cancer Institute

Daniel A. Hamstra, MD, PhD
William Beaumont Oakland University Medical School and Beaumont Health
Welcome

Andrew Vickers, PhD
Memorial Sloan Kettering Cancer Center
Update on Prostate-Specific Antigen Screening

Samir Taneja, MD
New York University
Role of MRI in Targeted Biopsy

Felix Y Feng, MD
University of California, San Francisco
Advanced Imaging and Biomarkers

Panel Question and Answer

Intensification Versus Deintensification in High-Risk Prostate Cancer

Srikala S. Sridhar, MD, FRCPC
Princess Margaret Cancer Centre, University Health Network
Medical Oncologist

Alberto Briganti, MD, PhD
Vita-Salute San Raffaele University
Urologist

Heather Ann Payne, FRCP, FRCR
University College London Hospitals NHS Foundation Trust
Radiation Oncologist

Panel Question and Answer
9:30 AM-10:00 AM Break
10:00 AM-11:30 AM General Session 2: Quality, Value, and Science for Optimizing Advanced Prostate Cancer Treatment

Karen E. Knudsen, PhD—Chair
Sidney Kimmel Cancer Center at Jefferson

Charles J. Ryan, MD—Chair
University of Minnesota

Beyond Survival: Clinical Decision Making for Castrate-Sensitive Prostate Cancer

Alicia K. Morgans, MD, MPH
Northwestern University
Quality of Life-Focused Decision Making for Castrate-Sensitive Prostate Cancer

TBD
Value-Based Decision Making for Castrate-Sensitive Prostate Cancer

Himisha Beltran, MD
Dana Farber Cancer Institute
Biologic Basis for Sequencing Novel Treatments for Metastatic Prostate Cancer

TBD
Practical Application of Genomic Assays in Clinical Decision Making

Panel Question and Answer
11:30 AM-1:00 PM Poster Session A: Prostate Cancer
With Complimentary Boxed Lunch
11:30 AM-1:00 PM Trials in Progress Poster Session A: Prostate Cancer
With Complimentary Boxed Lunch
11:45 AM-12:45 PM Trainee and Early-Career Networking Luncheon
1:00 PM-2:30 PM Oral Abstract Session A: Prostate Cancer
2:30 PM-3:00 PM Break
3:00 PM-4:30 PM General Session 3: Collaborative Management of Oligometastatic and Recurrent Prostate Cancer

Francesco Montorsi, MD—Chair
Universita Vita Salute San Raffaele

Michael J. Morris, MD—Chair
Memorial Sloan Kettering Cancer Center

Tumor Board: Oligometastatic Disease

Gert de Meerleer, MD, PhD
Gent University Hospital
Radiation Oncologist

Bridget F. Koontz, MD
Duke University Medical Center
Radiation Oncologist

Francesco Montorsi, MD
Universita Vita Salute San Raffaele
Urologist

Edward M. Schaeffer, MD, PhD
Northwestern University Feinberg School of Medicine
Urologist

Silke Gillessen, MD
Manchester Cancer Research Centre
Medical Oncologist

Michael J. Morris, MD
Memorial Sloan Kettering Cancer Center
Medical Oncologist

Panel Question and Answer
4:35 PM-5:30 PM Rapid Abstract Session A: Prostate Cancer
5:30 PM-6:30 PM Poster Session A: Prostate Cancer
Reception With Complimentary Wine and Cheese
5:30 PM-6:30 PM Trials in Progress Poster Session A: Prostate Cancer
Reception With Complimentary Wine and Cheese
5:45 PM- 6:30 PM Poster Walks